Sodium aminosalicylate controlled release - AGI Therapeutics

Drug Profile

Sodium aminosalicylate controlled release - AGI Therapeutics

Alternative Names: 4-ASA-Na - AGI Therapeutics; AGI-022

Latest Information Update: 18 Jan 2011

Price : $50

At a glance

  • Originator AGI Therapeutics
  • Class Anti-inflammatories; Antituberculars; Salicylates; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - Ulcerative colitis

Highest Development Phases

  • Phase I Ulcerative colitis

Most Recent Events

  • 09 Feb 2009 Clinical development is ongoing in Ireland
  • 27 Sep 2007 Clinical development is ongoing
  • 26 Jun 2005 Phase-I clinical trials in Ulcerative colitis in Ireland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top